Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
机构:[1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China[2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.[3]Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.[4]Respiratory Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, China.[5]Department of Respiratory Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.浙江大学医学院附属第一医院[6]Department of Respiratory Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.[7]Department of Respiratory and Critical Care Medicine, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[8]Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.[9]Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.[10]Department of Lung Cancer and Gastroenterology, Hunan Cancer Hospital, The Affiliated Tumour Hospital of Xiangya Medical School of Central South University, Changsha, China.[11]First Department of Lung Cancer Chemotherapy, The Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi, China.[12]Department of Oncology, Linyi Cancer Hospital, Linyi, China.[13]Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属同济医院[14]Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.[15]Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'An, China.[16]Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China.[17]Medical Oncology Department of Thoracic Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.[18]Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China.[19]Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.浙江省肿瘤医院[20]Hutchison MediPharma, Shanghai, China.
This study was supported by the National Key R&D Programme of China (2016YFC1303300) and the Shanghai Science and Technology Innovation Programme (19411950500), and was sponsored by Hutchison MediPharma and AstraZeneca.
第一作者机构:[1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China[*1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
通讯作者:
通讯机构:[1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China[*1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
推荐引用方式(GB/T 7714):
Lu Shun,Fang Jian,Li Xingya,et al.Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.[J].LANCET RESPIRATORY MEDICINE.2021,9(10):1154-1164.doi:10.1016/S2213-2600(21)00084-9.
APA:
Lu Shun,Fang Jian,Li Xingya,Cao Lejie,Zhou Jianying...&Su Weiguo.(2021).Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study..LANCET RESPIRATORY MEDICINE,9,(10)
MLA:
Lu Shun,et al."Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.".LANCET RESPIRATORY MEDICINE 9..10(2021):1154-1164